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Abstract
A reversible cell labelling method has been developed for non-destructive and non-invasive cell labelling and 
purification. Our method uses high affinity single strand DNA (ssDNA) aptamers against surface exposed target 
molecules on cells. The aptamers are subsequently removed from the cell surface using DNase nuclease treatment. We 
exemplified our method by labelling human acute lymphoblastic leukemia cells with Qdot-ssDNA aptamers, and 
restoring them to the label-free condition by treatment with Benzonase. Binding of the fluorescent-aptamers to the 
cells was evaluated by measuring fluorescence intensity and was further confirmed using flow cytometry. Removal of 
the aptamers can be achieved in ~10 min by the DNase nuclease digestion. Incubation of cells with aptamers or with 
the nucleases results in no apparent damage to the cells and does not affect their growth rates. The latter were 
equivalent to the rates measured for the untreated cells. Our method provides an alternative to traditional antibody-
based techniques and could be especially suitable for non-invasive reversible cell labelling and cell separations where 
maintaining native cell activity is needed.
Background
Separation of uniform phenotype cells whilst maintaining
their native states is important both for post genome cell
based studies and practical applications of those cells for
regenerative medicine. A number of cell separation meth-
ods have been reported to date, such as density-gradient
centrifugation, antibiotic screening and fluorescence-
activated cell sorting (FACS). The latter gained significant
popularity because of its simplicity and throughput. One
of the problems of the FACS and other antibody-based
labelling and separation techniques is that strong, often
nearly irreversible conjugation between antibody and
antigen molecules on cell surface may affect the function
of the targeted cells and their interaction efficacy with
other cells [1].
As an alternative to antibodies, we developed nucle-
otide based probes capable of binding target cell antigens
[2]. Aptamers are single-strand DNAs (ssDNA), RNAs or
modified nucleic acids. Systematic Evolution of Ligands
by Exponential Enrichment (SELEX) procedures for
molecular evolution and aptamer engineering have been
reported previously [3,4]. The development of ssDNA
aptamers for specific binding to live cells (Cell-SELEX)
expanded their potential for use in cell separation and
labelling [5-7]. However, the problem of removal of
aptamers from the target cells and restoring cells to their
original unlabelled state have not been addressed yet.
Here we describe a method for reversible labelling of the
cells with fluorescently tagged aptamers.
Materials and methods
Cell Culture
Human acute lymphoblastic leukemia cells, CCRF-CEM
(Dainippon Sumitomo Pharma, Osaka, Japan), were cul-
tured at 37°C under a 5% CO2 atmosphere in RPMI 1640
medium containing 10% heat-inactivated FBS, 100 IU/ml
penicillin, and 100 μg/ml streptomycin (Invitrogen,
Carlsbad, CA, USA).
Target Aptamer and Negative Control Aptamer
5'-Biotin-labeled ssDNA was used as the target DNA
aptamers for specific CCRF-CEM cell labelling, and ran-
dom sequence ssDNA consisting of the same length and
base composition as the target DNA aptamers were used
as negative control DNA aptamers [6]. Sequence of rec-
ognition area of specific DNA aptamer was 5'-TTT AAA
ATA CCA GCT TAT TCA ATT AGT CAC ACT TAG
AGT TCT AGC TGC TGC GCC GCC GGG AAA ATA
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Page 2 of 5CTG TAC GGA TAG ATA GTA AGT GCA ATC T-3',
and that of negative control ssDNA was 5'-TTT AAA
GGT CAT AGT AAT ATG AGG TAA TAC AAG CAA
TCG ACT AGG ACC AGC CTG TTA CGA CTA ATA
TCG GCC TGC ACA TGG TGA TCT TCT CAT T-3'.
Both ssDNAs were synthesized by Sigma Genosis (Hok-
kaido, Japan).
Qdot-aptamer Labeling
Figure 1 shows the procedure of cell labelling with 5'-bio-
tin-labeled ssDNA aptamers followed by nuclease diges-
tion. First, the cultured CCRF-CEM cells (intact cells)
were washed three times with culture medium (RPMI
1640 medium containing 10% heat-inactivated FBS, 100
IU/ml penicillin, and 100 μg/ml streptomycin), and then
incubated with the aptamer (4 μM) at 4°C for 30 min.
After the incubation, the cells were washed three times
with the cold culture medium to eliminate unbound
aptamers.
Next, the 5'-Biotin of the ssDNA aptamers bound to the
cells were labelled by addition of 0.1 μM Qdot-streptavi-
din conjugate (Qdot 525: emission maximum near 525
nm, Invitrogen Corp., Carlsbad, CA, USA). After 60 min
incubation at 4°C, the cells were washed three times with
the cold culture medium to remove excess free Qdot.
These Qdot-aptamer labelled cells (aptamer cells) were
then characterised by fow cytometry. To confirm the
specificity of aptamer binding, both the target-specific
aptamers and the negative control aptamers (irrelevant
sequences) were used.
Flow cytometry
Fluorescence measurements were made using an LSR II
flow cytometer (Becton Dickinson, CA, USA). Qdot fluo-
rescence of samples initially containing 106 cells in flow
Figure 1 An overview of the reversible aptamer labelling of live cells. Intact cells are labelled with biotin-aptamer conjugate, followed by strepta-
vidin-Qdot conjugates. Next, the Qdot-labelled aptamer cells are incubated with nuclease (DNase treated cells), this removes aptamers from the cells. 
The fluorescence intensities of intact cells, aptamer-labelled cells and DNase treated cells are compared using flow cytometery; possible cell damage 
is evaluated by measuring cell growth rates.
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cose, 5 mM MgCl2 and 1% FBS) were measured by count-
ing 30,000 events.
Nuclease Digestion
To remove the attached Qdot-aptamer from cells, the
aptamer cells were incubated in the pre-incubation cul-
ture medium containing 0.4 Unit/μL Benzonase nuclease
(Novagen, Darmstadt, Germany) at 37°C for 10 min.
After the incubation, the cells were washed three times
with the cold culture medium, and were characterised by
flow cytometry as described above.
Growth assay
To evaluate the invasiveness of nuclease digestion, the
growth rates of the three kinds of aptamer-treated cells
were measured after Benzonase nuclease treatment: cells
treated with target-specific aptamer, with the negative
control aptamer treatment, and those with no aptamer
treatment. Aptamer attachment and Benzonase nuclease
treatment proceeded as described above, and then cul-
tured in a medium for six days. The same number of non-
treated intact cells was also cultured as control. In each
sample, the number of cells collected by centrifugation
Figure 2 Fluorescence intensity of the cells labelled with Qdot-aptamer and treated with nuclease. Fluorescence changes following Qdot-
aptamer labelling of intact cells (blue: intact cells, red: aptamer labelled cells) (a). Fluorescence changes following DNase treatment of aptamer cells 
(red: aptamer labelled cells, green: DNase treated cells) (b). Comparison of unlabelled cells (blue) and DNase treated cells (green) (c). Comparison be-
tween unlabelled cells (blue), cells incubated with an irrelevant aptamer (cyan) and cells labelled with cell-specific aptamer (red) (d). Vertical axes show 
Side Scatter (SSC) values, and horizontal axes show fluorescence intensity measured at 525 nm.
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Page 4 of 5was counted using a Burker-Turk counting chamber. The
growth rate represented the cell number normalized by
those as 100% when growth-measurement started (day 0).
Results and Discussion
To this end we have developed and evaluated the proce-
dure of non-destructive and reversible fluorescent label-
ling of live cells using DNA-aptamers (see Figure 1). First
of all, we examined the labelling efficiency of the ssDNA
target aptamers on intact cells using flow cytometry. Fig-
ure 2(a) shows an increase in fluorescence intensity of
intact cells by over a hundred fold following the Qdot-
aptamer treatment. Subsequently, we removed the
attached DNA aptamers from cells using DNase nuclease
as shown in Figure 1. We then examined the effect of
DNase nuclease treatment on the Qdot-aptamer tagged
cells. Figure 2(b) shows the decrease of fluorescence
emission intensity of cells following the nuclease treat-
ment. To confirm the efficiency of aptamer removal, we
compared the fluorescence distributions of intact cells
and DNase nuclease treated Qdot-aptamer cells. As
shown in Figure 2(c), the distributions of the intact cells
and the DNase nuclease treated cells overlapped each
other. The results indicate that only the target-specific
aptamer was attached to the cells (i.e., the negative con-
trol aptamer did not interact with target cells), and that
the removal of Qdot-aptamer from the cells by DNase
nuclease treatment allowed recovery of the initial distri-
bution of intact cells. We also checked the interaction of
non-specific negative control DNA aptamer with the
intact cells. Figure 2(d) shows that the distribution of flu-
orescent intensities of Qdot-labelled negative control
aptamer treated cells overlapped with that of the intact
untreated cells, indicating lack of interaction and absence
of any noticeable effects on the treated cells.
To evaluate possible damage to cells during labelling or
nuclease digestion procedures we measured and com-
pared the growth rates of intact and treated cells. Figure 3
shows the growth curves of the three types of nuclease-
treated cells (cells incubated with the target-specific
Figure 3 Growth rates measured for the cells undergone aptamer labelling and its reversal by DNase treatment. The growth rate (vertical axis) 
shows an increase in cell numbers normalized to the initial cell numbers at the start of cultivation time (i.e., day 0). Growth rates for the cells labelled 
with cell-specific aptamer and undergone subsequent DNase treatment (open circles). Growth rates for the cells treated with an irrelevant aptamer 
(open triangles); unlabelled cells treated with Benzonase (cross); control cells - unlabelled and untreated (open squares) (N = 6).
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Page 5 of 5aptamer, with an irrelevant aptamer, or cells without an
aptamer) and the non-treated intact cells as control. For
five days, the growth rates of all three types of treated
cells were almost the same as that of the non-treated
intact cells. This result indicates that the aptamer label-
ling and DNase treatment have no apparent effect on the
cells growth rates.
The conventional SELEX method is aimed at the devel-
opment of DNA/RNA based drug-like molecules, and
therefore aptamers need to be resistant to nuclease activ-
ity under physiological conditions, e.g. to plasma 3'-exo-
nucleases [8,9]. Some of the previously reported aptamers
acquired stability to 3'-exonucleases from human plasma
[10,11]. The focus of this project was on the development
of digestible aptamers, and their removal from the target
cells by conventional DNases. Our approach is uniquely
applicable to nucleic acid aptamers only, because live cells
do not normally have DNAs associated with the cell sur-
face, therefore nuclease treatment is not expected to elicit
any functional effect. Traditional antibody-based
approached to cell labelling would not allow similar treat-
ment (protease digestion in the case of protein aptamers
or antibodies), because this would strip the cells of many
functionally important proteins exposed on the cell sur-
face. In our experiment, we used Benzonase nuclease, an
endonuclease with the ability to cleave the phosphodi-
ester bonds at many digestion sites, and confirmed
restoring the cells to a label-free condition.
In conclusion, we developed a reversible cell-labelling
procedure in which live cells are labelled with fluorescent
DNA aptamers, followed by their removal with nuclease
treatment. Our labelling procedure produces no notice-
able damage to the labelled cells. Our method is advanta-
geous over traditional antibody labelling because it allows
non-invasive cell separation and reversible cell labelling.
It has a great promise for a variety of applications ranging
from cell-based research to regenerative medicine.
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